quinapril has been researched along with Metabolic Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Helmy, T; Hooper, WC; Khan, BV; Lauten, WB; Lerakis, S; Menon, RG; Natarajan, R; Sola, S | 1 |
| Cheema, F; Khan, BV; Khan, QA; Merchant, N; Nagamia, S; Natarajan, R; Pandian, A; Patel, AD; Sola, S | 1 |
2 trial(s) available for quinapril and Metabolic Syndrome
| Article | Year |
|---|---|
Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Double-Blind Method; Erythrocytes; Female; Humans; Male; Metabolic Syndrome; Oxidative Stress; Quinapril; Superoxide Dismutase; Tetrahydroisoquinolines | 2004 |
The role of quinapril in the presence of a weight loss regimen: endothelial function and markers of obesity in patients with the metabolic syndrome.
Topics: Adiponectin; Adult; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Leptin; Male; Metabolic Syndrome; Middle Aged; Obesity; Prognosis; Quinapril; Tetrahydroisoquinolines; Vasodilation; Weight Loss | 2007 |